

Zimbabwe

Support for Vaccine: Measles

This Decision Letter sets out the Programme Terms of a Programme

1. **Country:** Zimbabwe

2. **Vaccine grant number:** ZWE-M-R-2ND

3. **Date of Decision Letter:** 28 September 2021

4. **Date of the Partnership Framework Agreement:** 17 May 2013

5. **Programme title:** New Vaccine Support (NVS), Measles, 2nd Dose Routine

6. **Vaccine type:** Measles

7. **Requested product presentation and formulation of vaccine:**

MR, 10 doses/vial, lyophilised

8. **Programme duration:¹** 2015-2022

9. **Programme Budget (indicative):²** (subject to the terms of the Partnership Framework Agreement, if applicable)

	2015-2020	2021	2022	2023	2024	2025	Total ³
Programme Budget(US\$)	953.051	252.013	153.692	-	-	-	1.358.756

10. **Vaccine introduction grant:**

Not applicable

11. **Product switch grant:**

Not applicable

¹This is the entire duration of the programme.

²This is the total amount endorsed by Gavi for the entire duration of the programme.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

³This is the amount that Gavi has approved.

12. Indicative annual amounts:³ (subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2015-2020	2021	2022
Number of vaccine doses	-	291.326	190.291
Number of AD syringes	-	434.900	258.000
Number of re-constitution syringes	-	72.500	43.100
Number of safety boxes	-	5.600	3.325
Annual Amounts (US\$)	953.051	252.013	153.692

13. Procurement agency: UNICEF Supply Division

14. Self-procurement:

Not applicable

15. Co-financing obligations:

Not applicable

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

Reports and other information :	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> ● vaccine stock levels including buffer stock, by end of March; ● number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. ● Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March</p> <p>15 May</p>
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>

18. Financial clarifications:

Not applicable

19. Other conditions:

In order to mitigate risks of stocking out in 2022, co-financing obligation associated with this programme should be fulfilled by August 31st 2022

Country has presented an official request to Gavi to switch from measles vaccine to measles-rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.

	2021
Number of doses of vaccines for Measles Second Dose approved by Gavi.	0
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	0
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi	0
Number of doses of Measles-Rubella vaccine to be funded by country.	0
Amount for Measles-Rubella vaccines to be funded by country in US\$ (excluding freight and insurance).	0